SG021 Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Virus Infection

Phase 2, randomised, double-blind trial in Viral lower respiratory tract infection (VLRTI), Influenza A infection, influenza B and 6 more comparing SNG001 with Placebo (2 arms). Primary endpoints: Part 1: Safety - occurrence and severity of adverse events and serious adverse events and Part 2: All-cause mortality within 28 days from randomisation. Started Oct 2025; status: completed.